Netoglitazone

InformationLanraplenib (GS-9876) Lanraplenib (GS-9876, GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI

InformationLanraplenib (GS-9876) Lanraplenib (GS-9876, GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI

InformationLanraplenib (GS-9876) Lanraplenib (GS-9876, GS-SYK) is a potent, highly selective and orally active inhibitor of Spleen Tyrosine Kinase (SYK) with IC50 of 9.5 nM. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI

The LPHN3 antibody from Proteintech is a rabbit polyclonal antibody to a peptide of human LPHN3. This antibody recognizes human,mouse,rat antigen. The LPHN3 antibody has been validated for the following applications: ELISA, WB, IP, FC analysis.

A potent inhibitor of EGFR-associated tyrosine kinase with an IC50 value of 0.012 &microM that also inhibits pp60c-src(+) kinase and CamKII with IC50 values of 0.5 and 0.2 &microM, respectively.

A potent inhibitor of EGFR-associated tyrosine kinase with an IC50 value of 0.012 &microM that also inhibits pp60c-src(+) kinase and CamKII with IC50 values of 0.5 and 0.2 &microM, respectively.

A potent inhibitor of EGFR-associated tyrosine kinase with an IC50 value of 0.012 &microM that also inhibits pp60c-src(+) kinase and CamKII with IC50 values of 0.5 and 0.2 &microM, respectively.

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3.Lenvatinib is an orally active

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3.Lenvatinib is an orally active

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3.Lenvatinib is an orally active

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3.Lenvatinib is an orally active

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3.Lenvatinib is an orally active